Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
MS research gears up for new drugs
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033
MS May Impair Cerebellar Regional Functional Connectivity
Episode 81 with Dr. Kaarina Kowalec
MS Patient, Ph.D.: Patience, the Rusty Adjective
MS Research Roundup: April 18, 2014
Dietary patterns not associated with the risk of multiple sclerosis
Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
Enzyme, Exposed
A Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis
Channeling MS
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
MS Research Roundup: December 2, 2014
CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
Neuromyelitis optica: not a multiple sclerosis variant.
Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.
Autologous hematopoietic stem cell transplantation in multiple sclerosis A phase II trial
Core Value of Amyloids
Multiple sclerosis and nutrition.
Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought.
Complementary/Alternative Medicine Use Changes With MS Progression

Pages

« first
‹ previous
…
37
38
39
40
41
42
43
44
45
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By